Men & BRCA: An Educational Panel
Join us for a panel discussion focused on men and BRCA gene mutations, including risk factors and surveillance options. Hear from BRCA mutation carrier and advocate, Gary Fuhrman, Penn Medicine physician Vivek Narayan, MD, MSCE, and Basser Genetic Counselor Avi Anantharajah, MS, LCGC. The discussion will be moderated by Basser Young Leadership Council member Louis Abrams, Esquire.
Thursday, January 27, 2022
7:00 PM – 8:00 PM ET
Louis Abrams, Esquire
Louis Abrams, Esquire, is an in-house attorney at a financial services company in Philadelphia, where he currently resides with his wife Jenny, son Maxwell, and his dog Pierre. In 2019, Louis learned that he carried a BRCA2 mutation. This diagnosis came after Louis lost his older sister Marion to BRCA-related breast cancer. Since then, Louis has been dedicated to raising money for BRCA-related research in conjunction with the Basser Center’s Young Leadership Council.
Avi Anantharajah, MS, LCGC
Avi Anantharajah, MS, LCGC, is a genetic counselor at the Basser Center for BRCA. A native of Toronto, Avi received his BS in Microbiology and Immunology from McGill University in 2017. Avi moved to Philadelphia in 2019 to complete his MS in Genetic Counseling at the University of Pennsylvania. Avi is a member of the Basser Center’s Young Leadership Council.
Gary Fuhrman is Chairman and Chief Executive Officer of GF Capital Management & Advisors, LLC, a New York based merchant banking firm founded in 2001 that makes principal investments in operating companies primarily in the media and consumer product sectors. Gary is a breast cancer survivor with BRCA-related cancers in a number of relatives. Gary has a BRCA2 mutation and feels strongly that the story of male breast cancer needs to be told. Gary will talk about his experience advocating for himself to gain knowledge and lower his risk. Gary graduated from the Wharton School of the University of Pennsylvania with a BS in Economics.
Vivek Narayan, MD, MSCE
Vivek Narayan, MD, MSCE, is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Pennsylvania’s Abramson Cancer Center. His clinical and research interests are specifically focused on the care of patients with advanced prostate and kidney cancers. He participates in the care of patients with hereditary predispositions to prostate cancer, and serves as principal investigator for numerous therapeutic clinical trials, including novel approaches for BRCA-associated prostate cancer.